http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2356134-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-48
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-421
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
filingDate 1999-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b676917a9402600909892d7dbd9e6eab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_062be24ce35535b975ba9d8bd1a8addd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87973bc2aa159f7015a7425d088ae0bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_151f1b2e9893f94a5ed5a88c08cde4fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03798399ef15c00228e2826c00ae8f64
publicationDate 2000-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2356134-A1
titleOfInvention Sulfonyloxazolamines as therapeutic active compounds
abstract The present invention relates to sulphonyloxazolamines of general formula (I), wherein R1, R2 represent independently from each other H, A, -(CH2)n-Ar or alkenyl with 2-6 C atoms, R1 and R2 together also represent a mononuclear saturated heterocycle with 1-2 N, O and/or S atoms, Z is H, A, CF3, NO2, Hal, OH, OA, NH2, NHA or NA2, A represents alkyl with 1-6 C atoms, Ar is Z-monosubstituted or Z-disubstituted phenyl, Hal is F, Cl, Br or I, n is 1 or 2 or the physiologically acceptable salts or solvates thereof. Said sulphonyloxazolamines are used as therapeutic active ingredients. The invention also relates to the use of sulphonyloxazolamines as therapeutic active ingredients and/or to the production of pharmaceutical preparations to combat diseases of the central nervous system. The invention further relates to a pharmaceutical preparation and the production thereof.
priorityDate 1998-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394775
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7504
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23583173
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394677
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID403
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416129785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416175303
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87717485
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID430084
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2761212
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3516
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396938
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393712
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID430084
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394761
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394669
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426256982
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414671846
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419488072
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394674
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID674
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457623688
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4432340
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559487
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457640656
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545267
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1549154
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426033928
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974

Total number of triples: 60.